{"id":"NCT01413204","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of TA-7284 as Monotherapy in the Treatment of Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-07","primaryCompletion":"2012-08","completion":"2012-08","firstPosted":"2011-08-10","resultsPosted":"2014-06-05","lastUpdate":"2014-06-05"},"enrollment":272,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"TA-7284 Low","otherNames":[]},{"type":"DRUG","name":"TA-7284 High","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"TA-7284 Low","type":"EXPERIMENTAL"},{"label":"TA-7284 High","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of TA-7284 as monotherapy in patients with type 2 Diabetes for 24 weeks administration.","primaryOutcome":{"measure":"Change in Hemoglobin A1c (A1C) From Baseline (NGSP Value)","timeFrame":"baseline and 24 weeks","effectByArm":[{"arm":"TA-7284 Low","deltaMin":-0.74,"sd":0.07},{"arm":"TA-7284 High","deltaMin":-0.76,"sd":0.07},{"arm":"Placebo","deltaMin":0.29,"sd":0.07}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":5,"countries":["Japan"]},"refs":{"pmids":["25010793"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":90},"commonTop":["Nasopharyngitis","Blood ketone body increased","Hypoglycaemia unawareness","Contusion","Pharyngitis"]}}